Omentin-1 and risk of myocardial infarction and stroke: Results from the EPIC-Potsdam cohort study.
The recently identified adipokine omentin-1 is inversely associated with body fatness, metabolic syndrome and cardiovascular disease (CVD) in cross-sectional analyses. However, prospective data on the association between plasma omentin-1 levels and future risk of CVD are lacking. The aim of the study was to investigate the relationship between omentin-1 and incident myocardial infarction (MI) and stroke.



We conducted a case-cohort study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort comprising a subsample of 2084 participants, including 50 CVD cases and 350 external incident CVD cases (mean follow-up of 8.2 ± 1.6 years). Prentice modified Cox regression adjusted for established CVD risk factors was used to estimate associations between omentin-1 and risk of MI and stroke, interactions were tested with cross-product terms.



After multivariable adjustment, omentin-1 was not significantly associated with risk of MI (HR per doubling omentin-1:1.17; 95%-CI:0.79-1.72; p = 0.43), but with higher risk of stroke (HR per doubling omentin-1:2.22; 95%-CI:1.52-3.22; p < 0.0001). In subgroup analyses, associations between omentin-1 and stroke risk were generally stronger in lower versus higher CVD risk groups. For example, risk of stroke was stronger in participants without metabolic syndrome (HR per doubling omentin-1:2.58; 95%-CI:1.64-4.07; p < 0.0001) compared to those with metabolic syndrome (HR per doubling omentin-1:1.21; 95%-CI:0.59-2.50; p = 0.60) (p for interaction = 0.05). Similar interactions were observed when participants were classified in low or high risk groups according to waist circumference, triglyceride, hsCRP or adiponectin levels.



Omentin-1 concentrations may be related to increased stroke risk. This association is stronger in metabolically healthy individuals.
Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; Research Group Cardiovascular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medical Center, Berlin, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany. Electronic address: Juliane.Menzel@dife.de.
Juliane
J
Menzel
Research Group Cardiovascular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; Institute of Epidemiology, Christian-Albrechts University Kiel, Kiel, Germany.
Romina
R
di Giuseppe
Institute for Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
Ronald
R
Biemann
Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany.
Clemens
C
Wittenbecher
Nutrition, Immunity and Metabolism Start-up Lab, Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Krasimira
K
Aleksandrova
Molecular Epidemiology Group, Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch, Berlin, Germany; German Center for Cardiovascular Disease (DZHK), Germany.
Tobias
T
Pischon
German Center for Diabetes Research (DZD), München-Neuherberg, Germany; Department of Internal Medicine, Division of Endocrinology, Diabetology, Nephrology, Vascular Disease and Clinical Chemistry, University of Tübingen, Tübingen, Germany.
Andreas
A
Fritsche
Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany; German Center for Cardiovascular Disease (DZHK), Germany.
Matthias B
MB
Schulze
Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Heiner
H
Boeing
Institute for Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
Berend
B
Isermann
Research Group Cardiovascular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medical Center, Berlin, Germany; German Center for Cardiovascular Disease (DZHK), Germany; Federal Institute for Risk Assessment, Department of Food Safety, Berlin, Germany.
Cornelia
C
Weikert
D054392:Adipokines / Q000097:blood / Q000502:physiology; D052242:Adiponectin / Q000378:metabolism; D002097:C-Reactive Protein / Q000378:metabolism; D015331:Cohort Studies; D016207:Cytokines / Q000097:blood* / Q000502:physiology; D005260:Female; D058851:GPI-Linked Proteins / Q000097:blood / Q000502:physiology; D006801:Humans; D037102:Lectins / Q000097:blood* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000097:blood* / Q000175:diagnosis; D012307:Risk Factors; D020521:Stroke / Q000097:blood* / Q000175:diagnosis; D014280:Triglycerides / Q000097:blood; D055105:Waist Circumference
C499918:ADIPOQ protein, human; D054392:Adipokines; D052242:Adiponectin; D016207:Cytokines; D058851:GPI-Linked Proteins; C432397:ITLN1 protein, human; D037102:Lectins; D014280:Triglycerides; D002097:C-Reactive Protein
Adipokines; Adiponectin; Intelectin-1; Risk factor